GALLEX 4 - Long-Term Extension Study to Evaluate Tesaglitazar Therapy in Patients With Type 2 Diabetes
NCT00300105
·
clinicaltrials.gov ↗
PHASE3
Phase
TERMINATED
Status
400
Enrollment
INDUSTRY
Sponsor class
Stopped
The development program has been terminated
Conditions
Type 2 Diabetes
Interventions
DRUG:
Tesaglitazar
Sponsor
AstraZeneca